FindTrial
Sign In

low dose ATG Effectively Prevents Acute Graft-versus-host Disease in Unrelated Donor Hematopoietic Stem Cell Transplantation

low dose ATG Effectively Prevents Acute Graft-versus-host Disease in Unrelated Donor Hematopoietic Stem Cell Transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-12002845
Enrollment
Unknown
Registered
2012-11-03
Start date
2007-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignacy

Interventions

HLA-matched unrelated:ATG 4.5mg/kg

Sponsors

the First Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. hematologic malignanciesto WHO criteria' 2. Aged from 14 years to 55 years old; 3. Physical score 0~2(WHO); 4. Sign the informed consent document.

Exclusion criteria

Exclusion criteria: 1. Contradiction of HSCT, e.g. uncontrolled active infection and severe cardiac, hepatic, renal and pulmonary disease; 2. Pregnant; 3. Mental disorder; 4. Physical score>3(WHO); 5. Cann't sign the informed consent document.

Design outcomes

Primary

MeasureTime frame
the incident of aGVHD;the incident of grade II-IVaGVHD;overall survival;transplant related mortality;relapse rate;—

Contacts

Public ContactHuang He
hehuangyu@126.com+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026